Drug intelligence / Profile preview

chitosan + γ-PGA nanoparticles + IFN-γ

Development stage
Preclinical
Modality
Cytokines & Interferons → Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
Administration
Intravenous, Intratumoral, Intraperitoneal, Subcutaneous
01

Overview

This is a combination therapy consisting of chitosan and poly(γ-glutamic acid) (γ-PGA) nanoparticles loaded with interferon-gamma (IFN-γ). Chitosan is a biocompatible polysaccharide, while γ-PGA is an anionic polypeptide; together they form stable nanoparticle complexes that can serve as drug delivery vehicles. These nanoparticles are designed to enhance the immunomodulatory and antitumor effects of IFN-γ by improving its delivery and bioavailability. The combination has demonstrated synergistic therapeutic potential in preclinical models of breast cancer, where it significantly reduced tumor progression and metastatic burden compared to either component alone. Mechanistically, the formulation acts both as an immunotherapy—by delivering type II interferon (IFN-γ)—and as a nanomedicine adjuvant that modulates the tumor microenvironment and immune response through Toll-like receptor activation[1][2]. This approach represents a novel strategy for anticancer therapy.

Other names
Ch/γ-PGA NPs + IFN-γChitosan/poly(γ-glutamic acid) nanoparticles incorporating IFN-γCh/IFN-γ/γ-PGA nanoparticles
02

Targets

TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)IFNGR1 (Interferon gamma receptor 1)

Beyond the preview

Go deeper on chitosan + γ-PGA nanoparticles + IFN-γ.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on chitosan + γ-PGA nanoparticles + IFN-γ.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call